Barchart Demo Center

Overview

Stocks

Stock Screeners

ETFs

Futures

Funds

Fund Screeners

Foreign Exchange

Sectors

News

Financial Calculators

Embedded Widgets

Portfolio

Screener

JSON Feeds

Symbol Overview

United States|Canada
English|French

Zymeworks Inc

(NYSE: ZYME)
Add to Portfolio
+2.53 (+7.51%)
as of 11:02 EDT

Last 36.20
Change +2.53 (+7.51%)
Open 34.81
Prev. Close 33.67
Today's Range
34.10
36.41
52wk Range
14.68
52.75
Volume 45296
Avg Volume 463567
Sector SIC-2834 Pharmaceutical Preparations

Perfomance Comparison

Name Today 3-Month 1-Year
ZYME +7.51% -24.36% +124.61%
DJIA +4.50% -23.94% -16.56%
S&P 500 +4.40% -20.99% -9.99%

Key Statistics

Annual EPS -3.68
Dividend Yield 0.00%
P/E Ratio N/A
Market Capitalization, $K 1562660
Weighted Alpha +110.56
Standard Deviation +0.81
Profit Margin N/A
Beta 1.47

Growth Rates

YTD -21.10%
1-Year +110.83%
3-Year +159.00%

Opinion

Sell Hold Buy

Recent Headlines

Zymeworks Announces First Patient Dosed in Phase 1b/2

BusinessWire via COMTEX - Wed Apr 01, 04:15PM EDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that its partner, BeiGene, Ltd., has dosed the first patient in a two-arm Phase 1b/2 trial evaluat(full story)
ZYME: 36.20 (+2.53)

Zymeworks Appoints Dr. Kelvin Neu to the Board of

BusinessWire via COMTEX - Mon Mar 16, 08:11AM EDT
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the appointment of Kelvin Neu, M.D., to its Board of Directors.(full story)
ZYME: 36.20 (+2.53)

Zymeworks Reports 2019 Year-End Financial Results

BusinessWire via COMTEX - Mon Mar 02, 04:15PM EST
Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today reported financial results for the year ended December 31, 2019.(full story)
ZYME: 36.20 (+2.53)

Zymeworks to Present at Raymond James 41st Annual

BusinessWire via COMTEX - Mon Feb 24, 08:30AM EST
Zymeworks Inc. (NYSE:ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today announced that the Company will present at the upcoming Raymond James Institutional Investors Conference taking (full story)
ZYME: 36.20 (+2.53)

Zymeworks Announces Closing of Public Offering and

BusinessWire via COMTEX - Mon Jan 27, 09:45AM EST
Zymeworks Inc. (NYSE: ZYME), a clinical stage biopharmaceutical company developing multifunctional biotherapeutics ("Zymeworks" or the "Company"), announced today the closing of its previously announced underwritten public offerin(full story)
ZYME: 36.20 (+2.53)